FDA: Genome editing therapies may use accelerated approval pathway
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited States